IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits

Since I upgraded IDEXX Laboratories, Inc. (NASDAQ: IDXX ) to a Buy rating in March 2025, the stock price has increased by more than 22%. The company delivered a strong quarterly result despite a decline in U.S. clinical visits. I reiterateMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a soli ...